Genscript Biotech Corporation
1548
Rangering i aksjer
#2023
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Aksjekurs
$4.45
Markedsverdi
$10.00B
Endring (1 dag)
1.63%
Endring (1 år)
114.95%
Land
HK
Handel Genscript Biotech Corporation (1548)
Kategori
Healthcare
Inntekter for Genscript Biotech Corporation (1548)
Inntekter i Jun 2026 TTM: $844.00M
Ifølge de nyeste økonomiske rapportene til Genscript Biotech Corporation er selskapets nåværende inntekter (TTM) $844.00M. I 2023 hadde selskapet inntekter på $839.53M en økning sammenlignet med inntektene i 2022, som var $625.70M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Genscript Biotech Corporation fra 2013 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $844.00M | 41.97% |
| 2024 | $594.49M | -29.19% |
| 2023 | $839.53M | 34.17% |
| 2022 | $625.70M | 27.67% |
| 2021 | $490.10M | 25.39% |
| 2020 | $390.85M | 42.98% |
| 2019 | $273.35M | 18.33% |
| 2018 | $231.02M | 51.34% |
| 2017 | $152.65M | 33.04% |
| 2016 | $114.74M | 32.32% |
| 2015 | $86.71M | 23.88% |
| 2014 | $69.99M | 16.45% |
| 2013 | $60.10M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | 1,395.77% |
US
|
|
| $2.23B | 163.98% |
US
|
|
| $15.74B | 1,765.44% |
AU
|
|
| $6.02B | 613.42% |
NL
|
|
| - | - |
CH
|
